Cargando…

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer

BACKGROUND AND PURPOSE: Treatment of intermediate and high-risk prostate cancer with a high BED has been shown to increase recurrence free survival (RFS). While high dose rate (HDR) brachytherapy, given as a boost is effective in delivering a high BED, many patients are not candidates for the proced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anwar, Mekhail, Weinberg, Vivian, Seymour, Zachary, Hsu, I. Joe, Roach, Mack, Gottschalk, Alex R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721063/ https://www.ncbi.nlm.nih.gov/pubmed/26792201 http://dx.doi.org/10.1186/s13014-016-0585-y

Ejemplares similares

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO)
por: Pasquier, David, et al.
Publicado: (2017)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023)

CyberKnife multisession stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for perioptic meningiomas: intermediate-term results and radiobiological considerations
por: Conti, Alfredo, et al.
Publicado: (2015)

Hypofractionated stereotactic radiotherapy for large arteriovenous malformations
por: Wang, Huan-Chih, et al.
Publicado: (2012)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
por: Pasquier, David, et al.
Publicado: (2018)

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
por: Nicholls, Luke, et al.
Publicado: (2020)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases
por: Księżniak-Baran, Dorota, et al.
Publicado: (2015)

Pre-plan parameters predict post-implant D(90) ≥ 140 Gy for (125)I permanent prostate implants
por: Alexander, Jes, et al.
Publicado: (2014)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost
por: Phuong, Christina, et al.
Publicado: (2022)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
por: Johansson, Silvia, et al.
Publicado: (2012)

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: Toxicity and quality of life assessment
por: Rucinska, Monika, et al.
Publicado: (2016)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
por: Aluwini, Shafak, et al.
Publicado: (2013)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Intracranial chordoma: radiosurgery, hypofractionated stereotactic radiotherapy and treatment outcomes
por: Napieralska, Aleksandra, et al.
Publicado: (2021)

Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS)
por: Pryor, David, et al.
Publicado: (2019)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
por: Gutschenritter, Tyler, et al.
Publicado: (2020)

Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost
por: van Schie, Marcel A., et al.
Publicado: (2019)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
por: Di Muzio, Nadia Gisella, et al.
Publicado: (2021)

Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
por: Tree, Alison, et al.
Publicado: (2013)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control
por: Meniai-Merzouki, F., et al.
Publicado: (2018)

Reproducibility and geometric accuracy of the fixster system during hypofractionated stereotactic radiotherapy
por: Lindvall, Peter, et al.
Publicado: (2008)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
por: Jiang, Xue-song, et al.
Publicado: (2012)

Cone-beam computed tomography in hypofractionated stereotactic radiotherapy for brain metastases
por: Ingrosso, Gianluca, et al.
Publicado: (2012)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer
por: Lin, Yu-Wei, et al.
Publicado: (2014)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Phase I/II Study of Extreme Hypofractionated Stereotactic Body Radiation Therapy Boost to Prostate for Locally Advanced, Node-Positive and Oligometastatic Cancer
por: Narang, Kushal, et al.
Publicado: (2020)

Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years
por: Aujla, Khush S., et al.
Publicado: (2019)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gcqgeplu1fl87nkob1lspe6s2o